01 / Contract Profile
75A50122C00047 Federal Contract Award
Agency code 7505
NO COST MOD TO EXTEND THE POP FOR CLIN0001 THROUGH AUGUST 28, 2031. EXERCISE AND FULLY FUND OPT CLIN0005B FOR THE PROCUREMENT OF 4,896 ORAL SUSPENSION TREATMENT COURSES IN THE AMOUNT OF $2,360,280.00. UPDATE G.1. CO. UPDATE G.3. CONTRACTOR'S POI
02 / Contract Size and Status
What is the recorded size and timing of this contract?
03 / Spending Trend
75A50122C00047 contract spending by fiscal year
Annual net obligations across the complete period available for this agency and PIID, from the first recorded fiscal year through the latest contract action.
Latest fiscal year obligations$2.36M
FY 2026Net obligationsComplete recorded range
| Fiscal year | Net obligations | Actions | Change |
|---|---|---|---|
| FY 2022 | $126.90M | 3 | — |
| FY 2023 | $0 | 1 | −100.0% |
| FY 2024 | $67.40M | 3 | — |
| FY 2025 | $17.10M | 1 | −74.6% |
| FY 2026 | $2.36M | 2 | −86.2% |
04 / Federal Buyer
Which organization manages this contract?
| Department | Contracting agency | Contracting office |
|---|---|---|
| HEALTH AND HUMAN SERVICES, DEPARTMENT OF | ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE | BARDA - ASPR / DAAPPO / BARDA DCMA |
05 / Contractor
Who holds this federal contract?
EMERGENT BIODEFENSE OPERATIONS LANSING LLC
UEI JLLWGQX6LNA5 · CAGE 81CF1
06 / NAICS Industries
Which industries classify this contract?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| 541714 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) | $213.77M | 10 | 100.0% |
07 / Products and Services
What products or services were purchased?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| AJ15 | GENERAL SCIENCE & TECHNOLOGY R&D SVCS; GENERAL SCIENCE & TECHNOLOGY; R&D FACILITIES & MAJ EQUIP | $213.77M | 10 | 100.0% |
08 / Place of Performance
Where is the work recorded?
DURHAM, DURHAM, NORTH CAROLINA, UNITED STATES
ZIP 277135246
09 / Contract Actions
What modifications and obligations were recorded?
| Signed date | Modification | Obligation | Contracting office | NAICS | PSC |
|---|---|---|---|---|---|
| Jul 8, 2026 | P00009 | $2.36M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AJ15 |
| Apr 21, 2026 | P00008 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AJ15 |
| Sep 5, 2025 | P00007 | $17.10M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AJ15 |
| Dec 12, 2024 | P00006 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AJ15 |
| Sep 19, 2024 | P00005 | $67.40M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AJ15 |
| Mar 19, 2024 | P00004 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AJ15 |
| Mar 29, 2023 | P00003 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AJ15 |
| Dec 16, 2022 | P00002 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AJ15 |
| Sep 8, 2022 | P00001 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AJ15 |
| Aug 26, 2022 | Base action | $126.90M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | AJ15 |
10 / Reading the Contract
How should this award record be interpreted?
Read the PIID as a transaction history, not as a single purchase price. Net obligations combine the base action with later increases, reductions, corrections, and deobligations recorded under the same contract.
Verify the buyer
Agency and office identify who manages the procurement relationship.
Follow modifications
Each action can change funding, scope, dates, or administrative terms.
Compare the market
Use NAICS, PSC, and the contractor profile to identify related buyers and competitors.